Algert Global LLC Has $348,000 Stock Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

Algert Global LLC lifted its stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) by 20.6% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 16,588 shares of the company’s stock after acquiring an additional 2,828 shares during the quarter. Algert Global LLC’s holdings in 4D Molecular Therapeutics were worth $348,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Allspring Global Investments Holdings LLC increased its position in shares of 4D Molecular Therapeutics by 702.1% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 3,457 shares of the company’s stock worth $110,000 after purchasing an additional 3,026 shares during the last quarter. Quest Partners LLC raised its position in 4D Molecular Therapeutics by 17,409.1% during the second quarter. Quest Partners LLC now owns 5,778 shares of the company’s stock worth $121,000 after acquiring an additional 5,745 shares in the last quarter. Entropy Technologies LP acquired a new stake in 4D Molecular Therapeutics in the first quarter valued at $239,000. Hsbc Holdings PLC acquired a new stake in 4D Molecular Therapeutics in the second quarter valued at $246,000. Finally, American Century Companies Inc. acquired a new position in shares of 4D Molecular Therapeutics during the 2nd quarter worth about $268,000. Institutional investors own 99.27% of the company’s stock.

Wall Street Analyst Weigh In

FDMT has been the subject of several recent analyst reports. Cantor Fitzgerald downgraded shares of 4D Molecular Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday, September 23rd. HC Wainwright reaffirmed a “buy” rating and issued a $36.00 price objective on shares of 4D Molecular Therapeutics in a research report on Thursday, September 19th. Leerink Partners reissued an “outperform” rating and set a $36.00 target price (down from $40.00) on shares of 4D Molecular Therapeutics in a report on Thursday, September 19th. BMO Capital Markets dropped their price target on 4D Molecular Therapeutics from $63.00 to $40.00 and set an “outperform” rating on the stock in a research note on Thursday, July 18th. Finally, Chardan Capital lifted their price objective on shares of 4D Molecular Therapeutics from $38.00 to $39.00 and gave the stock a “buy” rating in a research report on Thursday, September 19th. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, 4D Molecular Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $45.25.

Insider Transactions at 4D Molecular Therapeutics

In related news, insider Scott Bizily sold 1,996 shares of the business’s stock in a transaction that occurred on Thursday, July 11th. The stock was sold at an average price of $25.00, for a total value of $49,900.00. Following the completion of the sale, the insider now directly owns 6,781 shares in the company, valued at approximately $169,525. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Over the last ninety days, insiders have sold 4,246 shares of company stock valued at $105,508. 7.30% of the stock is currently owned by company insiders.

4D Molecular Therapeutics Price Performance

Shares of NASDAQ FDMT opened at $9.38 on Wednesday. 4D Molecular Therapeutics, Inc. has a one year low of $9.14 and a one year high of $36.25. The firm has a market cap of $484.97 million, a price-to-earnings ratio of -3.84 and a beta of 2.77. The stock’s fifty day moving average price is $14.29 and its two-hundred day moving average price is $20.97.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.63) EPS for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.09. The business had revenue of $0.01 million for the quarter, compared to the consensus estimate of $1.90 million. On average, equities analysts anticipate that 4D Molecular Therapeutics, Inc. will post -2.75 earnings per share for the current fiscal year.

4D Molecular Therapeutics Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.